Rs 14/Share Dividend: Pharma Stock Falls 4%, Prabhudas Lilladher Sees Upside In Shares, Buy

Board of directors of large cap Pharmaceuticals sector stock, Torrent Pharmaceuticals Ltd has announced an interim dividend of Rs 14 per share on January 25, 2023. Meanwhile, leading brokerage firm Prabhudas Lilladher has assigned buy call with a target price of Rs 1850 in its October 25, 2022 report. If you buy Torrent Pharmaceuticals now, you will potentially receive a return of 21%. Check key takeaways below:

1. Torrent Pharmaceuticals Declares An Interim Dividend Of Rs 14 Per Share

According to the regulatory filing of the company, "We would like to inform that the Board has at its meeting held today approved, inter-alia, an interim dividend of~ 14/- (280 %) per equity share of~ 5/- fully paid up. The dividend is expected to be paid/ dispatched on or around 14th February, 2023."

Earlier, the Company fixed Friday, 3rd February, 2023 as the Record Date for taking record of the Members of the Company for the purpose of payment of Interim Dividend.

2. Torrent Pharmaceuticals Stock Performance & Return

The last trading price of the stock is Rs 1530.50 apiece with an intraday fall of 1.73%. The stock's 52-week high is Rs 1722.70 apiece and 52-week low is Rs 1242.50 apiece, respectively.

The company has a market capitalisation of Rs 51,796.75 crore. The stock has given a return of 2% in last 6-months, 14% in last 1-year, and 115% in last 5-years. The stock witnessed a dip of 4% in last 3-months, and 3% in last 1-month.

3. Valuation

According to Prabhudas Lilladher, "In the near term, Curatio acquisition will increase TRP's net debt and we see this acquisition as EPS dilutive. Historically TRP have managed to integrate successfully Unichem and Elder acquisition which gives us comfort. We expect 18% EBITDA and 19% EPS CAGR over FY22-25E. We maintain our estimates and 'BUY' rating with TP of Rs 1,850/share, 17x EV/EBITDA to Sept 2024E."

4. About Torrent Pharmaceuticals

The company was a pioneer in initiating the concept of niche marketing in India and today is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC), according to its official website. The large cap stock was incorporated in 1972.

 

Disclaimer

The stock has been picked from the brokerage report of Prabhudas Lilladher. Greynium Information Technologies, the Author, and the respective Brokerage House are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.